Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Nirsevimab (Cvx 306) Alip Preservative-free 50 Mg/0.5 Ml Soln (CDM PHA17672) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 2, 2026 , from http://ppman.hank.ai/transparency/procedure/PHA17672/by-state?code_type=CDM
“Nirsevimab (Cvx 306) Alip Preservative-free 50 Mg/0.5 Ml Soln (CDM PHA17672) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/PHA17672/by-state?code_type=CDM. Accessed
July 2, 2026 .
“Nirsevimab (Cvx 306) Alip Preservative-free 50 Mg/0.5 Ml Soln (CDM PHA17672) by State,” HANK Price Transparency ,
accessed July 2, 2026 ,
http://ppman.hank.ai/transparency/procedure/PHA17672/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
PHA17672 — Nirsevimab (Cvx 306) Alip Preservative-free 50 Mg/0.5 Ml Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$4,010
National median
$3,341 – $4,232
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for PHA17672 (CDM), with interquartile range
State Median p25 p75
ND $4,010 $3,341 $4,232